134057-48-0

Basic information

• Product Name: 2-Benzothiazolamine,5-fluoro-6-methoxy-(9CI)
• Synonyms: 2-Benzothiazolamine,5-fluoro-6-methoxy-(9CI)
• CAS NO: 134057-48-0
• Molecular Formula: C₈H₇FN₂OS
• Molecular Weight: 198.2173832
• Product Categories: BENZOTHIAZOLE
• Mol File: 134057-48-0.mol

Chemical Properties

• Boiling Point: 357.94°C at 760 mmHg
• Flash Point: 170.276°C
• Appearance: /
• Density: 1.45g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.677
• CAS DataBase Reference: 2-Benzothiazolamine,5-fluoro-6-methoxy-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Benzothiazolamine,5-fluoro-6-methoxy-(9CI)(134057-48-0)
• EPA Substance Registry System: 2-Benzothiazolamine,5-fluoro-6-methoxy-(9CI)(134057-48-0)

Safety Data

• Hazardous Substances Data: 134057-48-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H7FN2OS/c1-12-6-3-7-5(2-4(6)9)11-8(10)13-7/h2-3H,1H3,(H2,10,11)

Upstream product

• 366-99-4 3-fluoro-4-methoxyaniline 
• 1147550-11-5 ammonium thiocyanate 

Downstream Products

• 953771-83-0 N-(cyclohexylmethyl)-5-fluoro-6-methoxybenzo[d]thiazol-2-amine 

Relevant articles and documents

BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS

The invention relates to 1,5-benzothiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also r

Benzothiazepine compounds and their use as bile acid modulators

The invention relates to 1,5-benzothiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also r

BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS

The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS

Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII); or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS

Disclosed are compounds of Formula (I) to (IV): [INSERT CHEMICAL STRUCTURE HERE] or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmace

6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING

Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF-1R.